Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Arq. bras. endocrinol. metab ; 58(3): 260-269, abr. 2014. tab, graf
Artigo em Inglês | LILACS | ID: lil-709343

RESUMO

Objective : The aim of this study was to explore the clinical characteristics of renal metastatic cancer, the methods for its detection by radioiodine (131I), and the response to 131I treatment in fourteen patients with renal metastases from differentiated thyroid carcinoma (DTC).Subjects and methods : DTC patients (n = 2,955) that received treatment with 131I were retrospectively analyzed. Scans (131I-WBS, 31I-SPECT/CT and/or 18F-FDG-PET/CT) were performed after an oral therapeutic dose of 131I. Therapeutic efficacy was evaluated based on changes in Tg and anatomical imaging changes at renal lesions.Results : Among these 14 patients, 11 had avidity for 131I, but three patients did not accumulate 131I after 131I treatment. In the 11 131I-positive renal lesions, 10 cases were detected by 131I-SPECT/CT combined with another imaging modality and one case by 131I-WBS combined with ultrasonography (US). In the three 131I-negative renal lesions, two cases were detected by 18F-FDG-PET/CT and one case by computed tomography (CT). In 11 patients with 131I-avid renal metastases, Serum Tg levels in 81.82% (9/11) patients showed a gradual decline, and 18.18% (2/11) of the patients showed a significant elevation. There was no marked difference in serum Tg before the last 131I treatment (Z = 0.157; p = 0.875). Only one patient presented partial response, eight patients exhibited stable disease, and renal metastases progressed in two patients showing progressive disease. No patients reached complete response.Conclusion : 131I-SPECT/CT, combined with another imaging modality after 131I-WBS, can contribute to the early detection of renal metastases of DTC. 131I therapy is a feasible and effective treatment for most DTC renal metastases with avidity for 131I. Arq Bras Endocrinol Metab. 2014;58(3):260-9.


Objetivo : O objetivo deste estudo foi analisar as características clínicas de metástases renais, os métodos para sua detecção por radioiodo (131I) e a resposta ao tratamento com 131I em 14 pacientes com metástases renais de carcinoma diferenciado da tireoide (DTC).Sujeitos e métodos Pacientes com DTC (n = 2.955) que receberam tratamento com 131I foram analisados retrospectivamente. 131I-PCI, 31I-SPECT/CT e/ou 18F-FDG-PET/CT foram feitos após uma dose terapêutica oral de 131I. A eficácia terapêutica foi baseada nas alterações da Tg e nas imagens anatômicas das lesões renais.Resultados : Dos 14 pacientes, 11 apresentaram lesões ávidas por 131I, mas três pacientes não acumularam 131I depois do tratamento com 131I. Nas 11 lesões renais positivas para 131I, 10 casos foram detectados por 131I-SPECT/CT combinado com outra modalidade de exame de imagem e um caso por 131I-WBS combinado com US. Nas três lesões renais negativas para 131I, dois casos foram detectados por 18F-FDG-PET/CT e um caso por tomografia computadorizada (TC). Em 11 pacientes com metástases renais ávidas por 131I, os níveis séricos de Tg em 81,82% (9/11) dos pacientes mostraram um declínio gradual e 18,18% (2/11) apresentaram uma elevação significativa. Não houve diferenças marcadas na Tg sérica antes do último tratamento com 131I (Z = 0,157; p = 0,875). Apenas um paciente apresentou resposta parcial, oito pacientes apresentaram doença estável e as metástases renais progrediram em dois pacientes que apresentaram doença progressiva. Nenhum dos pacientes apresentou resposta completa.Conclusão : 131I-SPECT/CT, combinada com outra modalidade de diagnóstico por imagem após 131I-PCI, pode contribuir para a detecção precoce de metástases renais de DTC. O tratamento ...


Assuntos
Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Carcinoma/secundário , Detecção Precoce de Câncer/métodos , Radioisótopos do Iodo/uso terapêutico , Neoplasias Renais/secundário , Doenças Raras , Neoplasias da Glândula Tireoide , Carcinoma , Carcinoma/radioterapia , Radioisótopos do Iodo , Neoplasias Renais , Neoplasias Renais/radioterapia , Estudos Retrospectivos , Doenças Raras , Doenças Raras/radioterapia , Tomografia Computadorizada de Emissão de Fóton Único , Tomografia Computadorizada por Raios X , Resultado do Tratamento , Tireoglobulina/sangue , Neoplasias da Glândula Tireoide , Neoplasias da Glândula Tireoide/radioterapia
2.
Rev. chil. pediatr ; 84(6): 628-633, dic. 2013. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-703285

RESUMO

Introducción: El tumor de Wilms (TW) es el tumor renal maligno más frecuente en la infancia, su tratamiento incluye, según su estadio y forma de presentación, cirugía precoz, radioterapia (RT) y quimioterapia (QT) según el protocolo PINDA. El objetivo es conocer los resultados de la serie histórica del Instituto Nacional del Cáncer (INC). Pacientes y Método: Revisión retrospectiva de todos los pacientes tratados con el diagnóstico de TW en el INC. Se describe la población de pacientes, tratamiento de RT recibidos, resultados de sobrevida global y factores pronósticos. Resultados: Desde septiembre de 1993 hasta diciembre de 2010 se trataron con RT 110 niños. La mediana de edad al diagnóstico fue de 3,6 años. La mediana de seguimiento fue de 128 meses desde el fin de RT. A junio de 2012, del total de 107 pacientes con seguimiento, 22 habían fallecido, 19 por progresión de enfermedad. Todos los pacientes que fallecieron lo hicieron antes de tres años desde el tratamiento. La sobrevida global a 2, 4, 12 años fue de 82 por ciento, 78 por ciento, 78 por ciento respectivamente. En análisis multivariado, cada día después de la cirugía sin comenzar la RT disminuye las probabilidades de sobrevida (p = 0,04). Conclusiones: El tratamiento del TW tiene un excelente pronóstico. La sobrevida, luego de los 3 años se estabiliza sin presentar eventos, indistintamente del grupo al que pertenezca el paciente. Dentro de los factores pronósticos, en pacientes con indicación de RT, esta se debe iniciar precozmente, al parecer lo más cercano a la cirugía.


Introduction: Wilms tumor (WT) is the most common form of malignant kidney tumor in childhood. According to PINDA protocols, its treatment includes, depending on stage and presentation, early surgery, radiotherapy (RT) and chemotherapy (CT). The objective of this work is to review the results of all patients of the National Cancer Institute (NCI) with this condition. Patients and Method: A retrospective review of all patients diagnosed with WT at the NCI was conducted. Patient population, RT treatment received and overall survival results were described and prognostic factors were searched. Results: From September 1993 to December 2010, 110 children were treated with RT. The median age at diagnosis was 3.6 years old. Median follow-up was 128 months after RT. In June 2012, out of a total of 107 patients with follow up, 22 had died, 19 due to disease progression. All deaths occurred within three years of treatment. Overall survival at 2, 4 and 12 years old was 82 percent, 78 percent, 78 percent respectively. A multivariate analysis showed that each day after surgery and without starting RT, the chances of survival decreased (p = 0.04). Conclusions: WT treatment has an excellent prognosis. Survival after 3 years stabilizes without presenting complications, regardless of the group to which the patient belongs. Among the prognostic factors for patients with RT prescription, this radiation should be started early, as close to the surgery as possible.


Assuntos
Humanos , Masculino , Feminino , Neoplasias Renais/radioterapia , Tumor de Wilms/radioterapia , Protocolos Antineoplásicos , Seguimentos , Análise Multivariada , Recidiva Local de Neoplasia , Neoplasias Renais/mortalidade , Neoplasias Renais/tratamento farmacológico , Estudos Retrospectivos , Análise de Sobrevida , Resultado do Tratamento , Tumor de Wilms/mortalidade , Tumor de Wilms/tratamento farmacológico
6.
Journal of the Egyptian National Cancer Institute. 1994; 6 (4): 838-843
em Inglês | IMEMR | ID: emr-106336

RESUMO

Sixty-two patients with metastatic renal cell carcinoma from January 1987 till December 1991 were collected. All patients, except six were subjected to radical nephrectomy. There were 53 cases with metastatic disease in lungs, liver, bone and brain. Patients received radiotherapy to the tumor bed, osseous and brain metastases. Concomitant with radiation, 38 patients received alpha-2 interferon [Interon A] for 12 weeks. A partial remission rate of 48%, was obtained with a median remission duration of 24 months. An overall survival of 78% at 3 years was achieved in patients who received the concomitant therapy. Survival rate was 38% in patients subjected to surgery and radiation. At 5 years the overall survival was 40% and 10% respectively. The results denote synergism between the 2 modalities immunotherapy and radiotherapy and heralds for further studies using higher doses of interferon for a longer time in metastatic renal cell carcinoma patients


Assuntos
Humanos , Masculino , Feminino , Neoplasias Renais/radioterapia , Radioimunoterapia/métodos , Interferons
8.
J Indian Med Assoc ; 1979 Feb; 72(4): 85-6
Artigo em Inglês | IMSEAR | ID: sea-100635
9.
Indian J Cancer ; 1968 Mar; 5(1): 62-7
Artigo em Inglês | IMSEAR | ID: sea-50553
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA